文献速递内脏/肾动脉与血管畸形

伊洛前列素用于不适合血运重建的持续性肠缺血患者

Iloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization.
PubMed 文献 · Ann Vasc Surg · 2017-03-18

本病例系列纳入2006至2015年间6例持续性肠缺血且经多学科团队判定不适合血运重建的稳定患者,采用伊洛前列素持续静脉输注治疗。6个月时4例出现治疗反应,其中3例完全停用肠外营养和镇痛药且无需肠切除,无严重不良事件。

要点

  • 不适合血运重建的持续性肠缺血患者可考虑伊洛前列素治疗
  • 伊洛前列素最大剂量2 ng/kg/min,每日6小时,连续4天静脉输注
  • 6例中4例在6个月时出现治疗反应,无严重不良事件

核心结论

  • 伊洛前列素对持续性内脏缺血患者可能具有有利效应,但需前瞻性试验证实。

研究设计与样本

  • 病例系列研究,纳入2006至2015年间一家三级中心连续随访的6例持续性肠缺血且不适合血运重建的稳定患者,平均年龄51岁。

主要发现

  • 内脏血管功能不全原因包括肠系膜上动脉血栓形成4例、腹腔干和肠系膜上动脉夹层1例、反复血管痉挛导致慢性非闭塞性肠系膜缺血1例。
  • 伊洛前列素以最大剂量2 ng/kg/min持续静脉输注,每日6小时,连续4天,无严重不良事件。
  • 6个月时4例出现治疗反应,其中3例完全停用肠外营养和镇痛药且无需肠切除。

关键数值与推荐

  • 治疗反应定义为6个月时镇痛药和肠外营养使用减少,且无需肠切除。
  • 血运重建可行性由多学科团队讨论排除,并在考虑血管活性治疗前获得知情同意。

临床怎么用

  • 对于经多学科团队判定不适合血运重建的持续性肠缺血稳定患者,可考虑伊洛前列素持续静脉输注治疗。

局限性

  • 本研究为病例系列,样本量小,结果需前瞻性试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent or chronic intestinal ischemic injury (i3) can lead to severe malnutrition and acute mesenteric ischemia. Although recommended, revascularization of splanchnic arteries is sometimes unrealizable. METHODS: We report a case series of iloprost use in consecutive stable patients with persistent i3 unsuitable for revascularization followed in a tertiary care center. The feasibility of revascularization was discussed and ruled out by a multidisciplinary team, and informed consent was obtained prior to consideration of a vasoactive therapy. Therapeutic response was defined at 6 months by a decrease in the use of analgesic and parenteral nutrition, and no need for intestinal resection. RESULTS: Between 2006 and 2015, 6 patients (mean age: 51) were included. Splanchnic vascular insufficiency was due to superior mesenteric artery (SMA) thrombosis (n = 4), dissection of the celiac trunk and SMA (n = 1), or repeated vasospasm resulting in chronic nonocclusive mesenteric ischemia (n = 1). Iloprost was delivered via continuous intravenous perfusion at a maximum dosage of 2 ng/kg/min for 6 hours/day on 4 consecutive days, without severe adverse events. Therapeutic response was observed in 4 patients, 3 of which completely stopped parenteral nutrition and analgesic with no need for intestinal resection. CONCLUSIONS: Our results are consistent with findings of a favorable effect of iloprost in patients with persistent splanchnic ischemia that should be confirmed in prospective trials.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nuzzo A, Soudan D, Billiauws L, et al. Iloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization. Ann Vasc Surg. 2017. PMID: 28323233. doi:10.1016/j.avsg.2016.10.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。